O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS

1 . A compound of Formula (I):

wherein:

ring A is selected from the group consisting of phenyl and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S;

the subscripts m and n are each independently 0 or 1;

R 1 is selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —X 1 —O—C 1-6 alkyl,

C 1-6 haloalkoxy, —X 1 -cyano, —NO 2 , —C(O)OR a , —NR a C(O)R b , —X 1 —C(O)NR a R b , —X 1 —OH, C 3-6 cycloalkyl, —X 1 —O—C 3-6 cycloalkyl, C 1-6 hydroxyalkynyl, —X 1 —NR a R b , —X 1 —S(O) 2 R a , —X 1 —S(O) 2 NR a R b , X 1 —X 1a —OR a , and a 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

R 2 is selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, C 1-6 haloalkoxy, and

—X 1 -cyano, wherein

each X 1 is independently selected from a bond and C 1-4 alkylene,

X 1a is 3- to 6-membered heterocycloalkylene having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and

R a and R b are independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 1-6 haloalkyl; and

Ar 1 is selected form the group consisting of phenyl, naphthyl, pyridin-2-one, and a 5- to 10-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R 1a substituents;

each R 1a is independently selected from C 1-6 alkyl, halo, C 1-6 haloalkyl, —X 2 —O—C 1-6 alkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, —C(O)R c , —C(O) 2 R c , —NR c C(O)R d , —O—C 1-4 alkylene-O—C 1-4 alkyl, —X 2 —C(O)NR c R d , —X 2 —S(O) 2 NR c R d , —X 2 —NR c R d , —C(O)NR c R d , —X 2 -cyano, —O—X 2 -cyano, —X 2 —S(O)R c , —X 2 —S(O) 2 R c , —X 2 —N(R d )S(O) 2 R c , —P(O)R c R d , —Y and —X 2 —OH; or

two R 1a groups on adjacent ring vertices combine to form a 4 to 6 membered cycloalkyl or heterocycloalkyl, having 0 to 2 heteroatoms as ring vertices independently selected from N, O, and S, and which is substituted with 0 to 4 groups independently selected from oxo, halo, C 1-4 alkyl, C 1-4 alkoxy, and C 1-4 haloalkyl;

wherein

each Y is independently selected from phenyl, benzyl, 4- to 6-membered heterocycloalkyl, and 5- or 6-membered heteroaryl, wherein each heterocycloalkyl and heteroaryl has 1 or 2 ring members independently selected from O, N and S; and each Y is substituted with 0, 1 or 2 groups independently selected from halo, oxo, C 1-4 alkyl, C 1-4 alkoxy, and C 1-4 haloalkyl;

each X 2 is independently selected from a bond and C 1-4 alkylene; and

each R c and R d are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 3-5 cycloalkyl and C 1-6 haloalkyl; and

R 3 is a member selected from the group consisting of

(i) C 3-6 cycloalkyl, C 6-11 bridged cycloalkyl and C 6-12 spirocycloalkyl;

(ii) 3- to 6-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

(iii) 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

(iv) 6- to 10-membered bridged heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

(v) 6- to 12-membered spiroheterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

(vi) hydrogen;

(vii) C 1-6 alkyl, or C 2-6 alkynyl,

wherein

each R 3 member of (i) through (v) is substituted with 0 to 4 R 3a substituents, each of which is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, C 1-6 haloalkyl, C 1-6 haloalkoxy, —X 3 —O—C 1-6 alkyl, —X 3 —OH, —NR e R f , —ONO 2 , 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, —NR e C(O)R f , —X 3 —NR e R f , —X 3 -cyano, and oxo; and

R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, C 1-3 haloalkyl, C 1-6 haloalkoxy, —O—C 1-6 alkyl, cyano, —OH, —NR e R f ,

—CONR e R f , and oxo, wherein

each X 3 is independently selected from a bond and C 1-4 alkylene, and

each R e and R f is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and —C 1-3 alkylene-C 3-6 cycloalkyl;

or a pharmaceutically acceptable salt thereof.

2 - 3 . (canceled)

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein ring A is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, imidazo[1,2-a]pyridinyl, 1,2,3-triazole, pyrazolyl, isoxazolyl, and imidazo[1,5-a]pyridinyl.

5 . (canceled)

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein ring A is pyridinyl.

7 - 8 . (canceled)

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1 and R 1 is selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —X 1 —O—C 1-6 alkyl, C 1-6 haloalkoxy, —X 1 -cyano, —X 1 —OH, C 3-6 cycloalkyl, —X 1 —NR a R b .

10 - 11 . (canceled)

12 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1 and R 1 is methyl.

13 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

14 - 16 . (canceled)

17 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 1 is selected from the group consisting of phenyl, pyridinyl, benzopyrazolyl, benzimidazolyl, imidazolyl, pyridazyl, imidazo[1,2-a]pyrimidinyl, oxazolo[4,5-b]pyridinyl, oxazolo[5,4-b]pyridinyl, thiazolo[4,5-b]pyridinyl, benzo[d]thiazole, indazolyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-b]pyridazinyl, and tetrazolo[1,5-a]pyridinyl, each of which is substituted with 0 to 4 R 1a .

18 . (canceled)

19 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 1 is pyridinyl substituted with 0 to 4 R 1a .

20 - 22 . (canceled)

23 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having Formula (Ia2), (Ib2), or (Ic2):

24 . (canceled)

25 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1a is independently selected from C 1-6 alkyl, halo, C 1-6 haloalkyl, —X 2 —O—C 1-6 alkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, —NR a R b , —X 2 -cyano, and —X 2 —OH.

26 - 27 . (canceled)

28 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1a is independently selected from methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl, difluoromethyl, methoxy, ethoxy, difluoromethoxy, cyclopropyl, —NH 2 , hydroxymethyl, and 1-hydroxyethyl.

29 - 34 . (canceled)

35 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 1-6 alkyl or C 2-6 alkynyl, and is substituted with 0 to 4 R 3b .

36 - 42 . (canceled)

43 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 6-12 spirocyclyl or C 3-6 cycloalkyl, each of which is substituted with 0 to 4 R 3a .

44 - 45 . (canceled)

46 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is a 3- to 6-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted with 0 to 4 R 3a .

47 - 50 . (canceled)

51 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is a 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted with 0 to 4 R 3a .

52 - 59 . (canceled)

60 . A compound selected from those in Table 1 or a pharmaceutically acceptable salt thereof, in Table 2 or a pharmaceutically acceptable salt thereof, and Table 3 or a pharmaceutically acceptable salt thereof.

61 . A pharmaceutical composition comprising a compound of claim 1 , and at least one pharmaceutically acceptable excipient.

62 . A method for treating a disease characterized by overexpression of Polθ in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease is a cancer.

63 . (canceled)

64 . A method of treating a homologous recombinant (HR) deficient cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

65 . (canceled)

66 . A method for treating a cancer in a patient in need thereof, wherein the cancer is characterized by a reduction or absence of BRCA gene expression, the absence of the BRCA gene, or reduced function of BRCA protein, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

67 . The method of claim 62 , wherein the cancer is lymphoma, rhabdoid tumor, multiple myeloma, uterine cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer, mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper aerodigestive cancer, leukemia, kidney cancer, skin cancer, esophageal cancer, and pancreatic cancer.

68 - 71 . (canceled)